Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2020

View Archived Issues

Benzoxazole analogues capable of reducing ChemR23 expression on monkey pDCs in vivo

ImmTAV molecules redirect T cells to lyse HBV DNA-integrated and virally infected cells in vitro

New phase II trial opens in France to study XAV-19 in COVID-19-induced moderate pneumonia

Athira opens enrollment in phase II trial of ATH-1017 for mild to moderate Alzheimer's

First-in-human study of progerinin

Discovery of novel potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

Inhibition of alpha-KG-producing enzymes is therapeutic in diffuse intrinsic pontine glioma models

Novel FARS2 gene mutation causes spastic paraplegia 77

Tissue-specific p53 effects could aid drug development

Merck KGaA divulges PTPN11 inhibitors

Chinese researchers disclose ENPP2 inhibitors

Sunshine Lake Pharma patent reveals influenza virus replication inhibitors

1st Bio Therapeutics identifies ABL1 inhibitors

ADC Therapeutics starts enrollment in phase III study of loncastuximab tesirine in DLBCL

Optikira synthesizes new ERN1 inhibitors

Phase I/IIa data published for BIVV-001 in patients with hemophilia A

Ascletis begins phase I study of ASC-41 in healthy subjects

Akeso begins first-in-human study of COVID-19 treatment candidate AK-119

CIP2A as new diagnostic biomarker in Parkinson's disease

SAGE-718 studied in phase II for Parkinson's disease mild cognitive impairment

New antibody-mediated multiple sclerosis model developed

Confirmatory phase III trial of Pacev in urothelial cancer meets primary endpoint of OS

Shanghai Henlius Biotech begins phase I study with pertuzumab biosimilar HLX-11

APPA enters phase II trial for osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...